Daily Sepsis Research Analysis
Analyzed 17 papers and selected 3 impactful papers.
Summary
Three clinically oriented sepsis studies stand out today: echocardiography-derived hemodynamic phenotypes in sepsis predict 30-day ICU mortality; a rapid ID/AST platform markedly shortens time to targeted therapy with high concordance to standard methods; and the Phoenix Sepsis Score is externally validated in a large pediatric cohort with excellent discrimination.
Research Themes
- Hemodynamic phenotyping for risk stratification in sepsis
- Rapid molecular diagnostics and antimicrobial stewardship
- Pediatric sepsis scoring and external validation
Selected Articles
1. Early hemodynamic phenotyping in sepsis using transthoracic echocardiography: A proof-of-concept study in a north African ICU.
In two prospective ICU cohorts (n=78), k-means clustering of eight early TTE variables identified three phenotypes—hemodynamically optimized, vasoplegic, and myocardial depressed—with markedly different 30-day ICU mortality (28% vs 59% vs 69%). The myocardial depressed phenotype was independently associated with higher risk of ICU death.
Impact: This is the first echocardiography-informed hemodynamic phenotyping in an African ICU, demonstrating prognostic relevance and supporting individualized management strategies in sepsis.
Clinical Implications: Early TTE-based hemodynamic phenotyping could guide tailored choices of fluids, vasopressors, and inotropes, prioritizing myocardial support in the depressed phenotype and vasopressors in vasoplegia.
Key Findings
- Three TTE-derived phenotypes were identified: optimized (n=25), vasoplegic (n=27), and myocardial depressed (n=26).
- 30-day ICU mortality differed significantly: 28% vs 59% vs 69% (p<0.001).
- Myocardial depressed phenotype had higher adjusted hazard of ICU death (HR 2.90; 95% CI 1.24-6.79).
Methodological Strengths
- Prospective data collection with standardized early TTE within 24 hours
- Unsupervised clustering (k-means) on clinically relevant hemodynamic indices with survival analysis
Limitations
- Small sample size and single-region ICU setting
- Post-hoc exploratory design with potential residual confounding and model selection bias
Future Directions: Prospective, multicenter validation with protocolized phenotype-guided interventions to test causal impact on outcomes.
BACKGROUND: Cardiovascular dysfunction in sepsis is heterogeneous and contributes to poor outcomes. Hemodynamic phenotyping may delineate pathophysiologically distinct subgroups with implications for prognosis and individualized management. No studies have evaluated such phenotypes in African intensive care units (ICUs). We aimed to explore cardiovascular phenotypes in patients with sepsis using clinical and echocardiographic variables. METHODS: We conducted a post-hoc exploratory analysis of two prospective ICU cohorts. Adults w
2. Novel rapid diagnostic system for pathogen identification and antimicrobial susceptibility testing: clinical utility in ICU patients with sepsis.
In ICU patients with sepsis and positive blood cultures, the Accelerate Pheno system reduced total turnaround time for organism ID and AST from about 72 hours to 29 hours. It guided antimicrobial decisions in 67% of cases and showed high concordance with standard AST, especially for Gram-positive organisms.
Impact: Demonstrates real-world clinical utility of rapid ID/AST in sepsis management, enabling earlier targeted therapy with high agreement to standard methods.
Clinical Implications: Implementation of rapid ID/AST can accelerate de-escalation or escalation decisions, reduce empiric broad-spectrum exposure, and potentially improve outcomes and stewardship metrics.
Key Findings
- Total turnaround time shortened from ~3 days to 29 hours (p<0.001).
- Therapeutic decisions were guided by rapid results in 67% of cases (20% de-escalation, 37% escalation, 43% no change among those guided).
- AST concordance was 100% for Gram-positive and 95% for Gram-negative organisms; a minority of very major, major, and minor errors occurred.
Methodological Strengths
- Head-to-head comparison with standard-of-care methods in a real-world ICU cohort
- Clinically meaningful endpoints including turnaround time and antimicrobial decision impact
Limitations
- Retrospective single-platform evaluation with 32% incomplete ID due to panel limits or technical issues
- Limited performance in polymicrobial samples and small number of AST discrepancies that may impact decisions
Future Directions: Prospective multicenter trials to assess patient-centered outcomes, cost-effectiveness, and integration with stewardship workflows.
BACKGROUND: This study aimed to evaluate a molecular diagnostic system for the rapid identification of pathogens and determination of their antimicrobial susceptibility. By comparing its performance with standard microbiological methods, the study assessed whether the new system could shorten the time to optimal antimicrobial therapy and reliably complement, or potentially replace, conventional diagnostics. METHODS: A retrospective study was conducted to evaluate the performance of the Accelerate Pheno sys
3. External validation of the Phoenix Sepsis Score in Singapore: a retrospective cohort study.
In 25,202 hospitalized children with suspected infection, a PSS ≥2 identified a high-risk subgroup with 8.5% mortality, yielding sensitivity 68.3% and specificity 97.6% for in-hospital death. Discrimination was excellent (AUROC 0.90; AUPRC 0.36), outperforming the original cohort.
Impact: Provides robust external validation of a data-driven pediatric sepsis score in a high-resource Asian setting, supporting its use as a benchmark in research and potential clinical triage.
Clinical Implications: PSS can serve as a specific trigger for escalation of care, focused monitoring, or enrollment in interventional studies among children with suspected infection.
Key Findings
- Among 25,202 children, 660 (2.6%) had PSS ≥2 and 411 (1.6%) met septic shock criteria.
- PSS ≥2 associated with 8.5% mortality; sensitivity 68.3% (95% CI 57.5–78.4%) and specificity 97.6% (95% CI 97.4–97.8%).
- Overall discrimination was excellent: AUROC 0.90 (95% CI 0.86–0.94) and AUPRC 0.36 (95% CI 0.24–0.47).
Methodological Strengths
- Very large single-center cohort with standardized application of PSS
- Robust performance metrics including AUROC and AUPRC with confidence intervals
Limitations
- Retrospective design with potential selection bias (broad-spectrum antibiotic–treated population)
- Generalizability to lower-resource settings or different care pathways may be limited
Future Directions: Prospective validation across diverse health systems and assessment of PSS-guided triage or treatment pathways on patient outcomes.
OBJECTIVE: The Phoenix Sepsis Score (PSS) was derived and validated in 10 healthcare systems internationally. We sought to perform an external validation of the PSS among children with suspected infection in a high-resource country in Asia. DESIGN: Retrospective cohort study. SETTING: A tertiary paediatric hospital in Singapore, between 1 January 2020 and 31 December 2024. PATIENTS: Children <18 years old hospitalised with suspected infection who received broad-spectrum intravenous antibiotics. INTERVENTIONS: